Choose markets with evidence. Enter them with an operating plan.

Is there enough addressable demand at a price the market will accept?

Size alone is not attractiveness. What matters is the portion of demand your offer can realistically reach, at a price point that survives local reference pricing and procurement behaviour.

What is assessed

• Reachable segment size for your specific offer, not the category total
• Prevailing price references and willingness to pay
• Buying frequency, contract length, and expansion potential per account
• Currency, payment terms, and margin structure after local cost to serve

Weak evidence looks like: A national market-size figure with no segmentation and no pricing reference.

Does this market advance the strategy, or merely add revenue?

A market can be commercially viable and still be the wrong move. Fit is judged against the direction of the business, the portfolio it already carries, and what leadership can absorb.

What is assessed

• Alignment with the segments and use cases the company intends to own
• Whether the market strengthens or dilutes the existing proposition
• Reference value: does winning here make the next market easier?
• Opportunity cost against other candidate markets and domestic growth

Weak evidence looks like: Entry justified by an inbound enquiry or a single relationship.

Can you actually reach the buyer, and through what route?

Access is often the binding constraint. Demand that exists but cannot be reached economically behaves, in practice, like demand that does not exist.

What is assessed

• How the buying decision is made locally, and by whom
• Whether direct, partner-led, distributor, or marketplace routes dominate
• Cost and length of the route to first revenue on each viable path
• Credibility requirements: local references, presence, certifications

Weak evidence looks like: An assumption that the home-market go-to-market motion transfers unchanged.

What does it cost to be heard, and can that position be held?

Intensity is not just how many competitors exist. It is how entrenched they are, how buyers switch, and how much sharper the positioning must be to register at all.

What is assessed

• Incumbent density, incumbent origin, and switching behaviour
• Category maturity and how buyers currently frame the problem
• Whether differentiation is structural or purely narrative
• Acquisition cost implied by the level of noise in the category

Weak evidence looks like: A competitor list with no view of how buyers actually choose between them.

How much of the offer has to change, and who owns that change?

Localization ranges from language and commercial convention through to product form, packaging, pricing model, and support expectations. The depth required is a cost and a timing driver.

What is assessed

• Language, tone, and commercial convention in the buying process
• Product, packaging, or service-model adaptation required
• Pricing model form: subscription, licence, tender, usage
• Support, documentation, and service-level expectations

Weak evidence looks like: Treating localization as a translation task assigned late in the plan.

Can the operation be staffed and run to the standard you expect?

Feasibility is about whether the required roles exist locally, at a cost the model supports, and whether the operating structure around them can be run consistently from the centre.

What is assessed

• Availability of the specific commercial and delivery roles required
• Compensation benchmarks against the assumed cost base
• Time zone, language, and management overlap with the centre
• Whether processes and systems can extend without being rebuilt

Weak evidence looks like: Headcount plans built from home-market salary and productivity assumptions.

Are there credible partners, and is partnering the faster route?

In many markets the partner landscape determines both speed and ceiling. A strong ecosystem can compress the route to first revenue; a thin one quietly pushes the plan toward direct build.

What is assessed

• Depth and quality of resellers, integrators, distributors, or referrers
• Whether existing partners already serve your target buyer
• Commercial terms partners expect, and their effect on margin
• Concentration risk if one partner carries the market

Weak evidence looks like: A partner strategy named in the plan with no identified candidates.

What must be resolved by qualified specialists before commitment?

AtlasFlow maps where regulatory, legal, employment, and tax questions sit on the critical path and coordinates the qualified specialists who answer them. AtlasFlow does not provide legal, tax, or regulated advice.

What is assessed

• Entity, contracting, and employment structure questions to be scoped
• Sector-specific licensing or certification that may gate entry
• Data, privacy, and cross-border handling obligations to be confirmed
• Which decisions cannot proceed until specialist counsel has responded

Weak evidence looks like: Regulatory work treated as a post-launch clean-up item.

Can the organisation fund it, sequence it, and actually lead it?

The most common reason expansion stalls is not market choice but organisational capacity. Funding, sequencing, and named ownership decide whether the plan survives contact with the business.

What is assessed

• Investment required to reach a defensible position, not just to launch
• Sequencing against other commitments already on the roadmap
• Named executive ownership and decision authority in the market
• Agreed review points and the conditions under which you would stop

Weak evidence looks like: A business case with a launch budget but no operating budget beyond it.